The report highlights SINOVAC's commitment to ""making vaccines a global public good"" and details the company's achievements throughout the year, including the continued growth of its regular product sales revenue, the supply of 38.98 million doses of vaccines globally, and the establishment of joint ventures in countries such as Türkiye and Colombia. SINOVAC also emphasizes its dedication to R&D and innovation, as well as its commitment to promoting vaccine production technology worldwide. The report also details SINOVAC's efforts in promoting green production, building a green industry chain, and ensuring supply chain resilience. SINOVAC's dedication to talent development and employee welfare is also outlined, showcasing the company's commitment to creating a harmonious and supportive workplace.
